In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Juno Therapeutics Inc. (NASDAQ:JUNO) reported that has picked up 10,350,833 of common stock as of 2017-03-27.
The acquisition brings the aggregate amount owned by Celgene Switzerland Llc. to a total of 10,350,833 representing a 9.7% stake in the company.
For those not familiar with the company, Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
A glance at Juno Therapeutics Inc. (NASDAQ:JUNO)’s key stats reveals a current market capitalization of 2.20 Billion based on 106.02 Million shares outstanding and a price at last close of $20.85 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-03-10, Evnin picked up 8,000 at a purchase price of $22.11. This brings their total holding to 56,990 as of the date of the filing.
On the sell side, the most recent transaction saw Azelby unload 12,921 shares at a sale price of $24.14. This brings their total holding to 35,719.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Juno Therapeutics Inc. (NASDAQ:JUNO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
